Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
Autore:
Garnero, P; Buchs, N; Zekri, J; Rizzoli, R; Coleman, RE; Delmas, PD;
Indirizzi:
Hop Edouard Herriot, INSERM, U403, Res Unit, F-69437 Lyon 03, France Hop Edouard Herriot Lyon France 03 03, Res Unit, F-69437 Lyon 03, France SYNARC, Lyon, France SYNARC Lyon FranceSYNARC, Lyon, France Univ Hosp Geneva, Div Bone Dis, Geneva, Switzerland Univ Hosp Geneva Geneva Switzerland , Div Bone Dis, Geneva, Switzerland YCR Dept Clin Oncol, Sheffield, S Yorkshire, England YCR Dept Clin Oncol Sheffield S Yorkshire England , S Yorkshire, England
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 4, volume: 82, anno: 2000,
pagine: 858 - 864
SICI:
0007-0920(200002)82:4<858:MOBTFT>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE REPLACEMENT THERAPY; C-TERMINAL TELOPEPTIDE; PYRIDINIUM CROSS-LINKS; I COLLAGEN; DEGRADATION PRODUCTS; ALKALINE-PHOSPHATASE; PAGETS-DISEASE; URINARY PYRIDINOLINE; BIOCHEMICAL MARKERS; DIAGNOSTIC-VALUE;
Keywords:
bone markers; prostate cancer; bone metastases; type I collagen; bisphosphonate;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Garnero, P Hop Edouard Herriot, INSERM, U403, Res Unit, Pav F, F-69437 Lyon 03, France Hop Edouard Herriot Pav F Lyon France 03 69437 Lyon 03, France
Citazione:
P. Garnero et al., "Markers of bone turnover for the management of patients with bone metastases from prostate cancer", BR J CANC, 82(4), 2000, pp. 858-864

Abstract

Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidencefor increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (alpha CTX) and beta isomerized (beta CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg), Levels of all bone formation and bone resorption markers were significantly (P < 0.006-0.0001) higher in patients withprostate cancer and bone metastasis than in patients with benign prostatichyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary alpha CTX, 149% for urinary beta CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary alpha CTX, urinary beta CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increasein bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients. (C) 2000 Cancer Research Campaign.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 13:14:23